The short version of 胰高血糖素受体 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-05. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
=== Phimosis, balanitis and balanoposthitis === Phimosis is the inability to retract the foreskin over the glans penis. At birth, the foreskin cannot be retracted due to adhesions between the foreskin and glans, and this is considered normal (physiological phimosis). Over time the foreskin naturally separates from the glans, and a majority of boys are able to retract the foreskin by age three. Less than one percent are still having problems at age 18. If the inability to do so becomes problematic (pathological phimosis) circumcision is a treatment option. A preputioplasty, where the foreskin is surgically widened instead of removed, is another possible surgical treatment option for phimosis. This pathological phimosis may be due to scarring from the skin disease balanitis xerotica obliterans (BXO), repeated episodes of balanoposthitis or forced retraction of the foreskin. Steroid creams are also a reasonable option and may prevent the need for surgery including in those with mild BXO. The procedure may also be used to prevent the development of phimosis. Phimosis is also a complication that can result from circumcision. An inflammation of the glans penis and foreskin is called balanoposthitis, and the condition affecting the glans alone is called balanitis. Most cases of these conditions occur in uncircumcised males, affecting 4–11% of that group. The moist, warm space underneath the foreskin is thought to facilitate the growth of pathogens, particularly when hygiene is poor.
== Haemovigilance == Haemovigilance is the set of surveillance procedures that monitors, reports, investigates, and analyses adverse events related to transfusion. It covers the entire blood transfusion chain, from blood donation and processing of blood and its components, through to their provision and transfusion to patients. These reporting systems play a fundamental role in enhancing patient safety by learning from failures and then putting system changes in place to prevent them in the future. The TP's involvement in haemovigilance within the hospital setting, starts with education of those involved in the transfusion process so they can recognise, manage, and report reactions. The TPs roles ensures clinical transfusion incidents, transfusion reactions, specimen labelling errors are investigated and report data to haemovigilance governance programmes (e.g. SHOT in the UK). By conducting process reviews and communicating directly with the relevant colleagues and patients, the TP can provide essential details that are needed to complete investigations. This information can assist with determining the transfusion reaction type and recommendations for future transfusion plans for the patient, or the implementation of corrective and preventative measures. National haemovigilance schemes e.g. SHOT provide the TP with a resource for educating clinical colleagues on transfusion safety and recommendations for best practice.
The "Passover Ration" (officially called the Meal, Religious, Kosher for Passover) contains packages of Matzoh crackers and has beef, chicken (served on the bone), or salmon entrees. Each meal is in its own packet and come 12 packets to a case. For less strictly-observing servicemembers, non-certified "pork-free" menus of the regular MRE are available. The DLA offers Meal, Ready-to-Eat (MRE), Pork-Free, Individual, which consist of 12 menus selected from the regular roster of 24.
===== MeSH D08.811.399.403 – dna topoisomerases ===== MeSH D08.811.399.403.483 – dna topoisomerases, type i MeSH D08.811.399.403.483.249 – dna topoisomerases, type i, archaeal MeSH D08.811.399.403.483.300 – dna topoisomerases, type i, bacterial MeSH D08.811.399.403.483.500 – dna topoisomerases, type i, eukaryotic MeSH D08.811.399.403.741 – dna topoisomerases, type ii MeSH D08.811.399.403.741.249 – dna topoisomerases, type ii, archaeal MeSH D08.811.399.403.741.300 – dna topoisomerases, type ii, bacterial MeSH D08.811.399.403.741.300.500 – dna gyrase MeSH D08.811.399.403.741.300.750 – dna topoisomerase iv MeSH D08.811.399.403.741.500 – dna topoisomerases, type ii, eukaryotic
Sources: en.wikipedia.org
=== Lobbying the FDA === In 2011, the FDA made it a priority to clarify the requirements for approval for such a closed-loop monitoring and drug delivery device for T1D, and announced it was preparing draft guidelines. Breakthrough T1D launched a campaign to influence those guidelines to be lenient. After the first closed-loop device was approved in 2016, Breakthrough T1D lobbied insurance companies to cover it. The campaign also put resources into educating people with diabetes on how to navigate health insurance in the United States, and into lobbying Congress to continue funding diabetes research through the NIH. The FDA lobbying campaign was part of a gradual realignment of the organization to focus on issues other than helping find a cure for type 1 diabetes, but to help treat and manage the disease. This broadened scope meant that the organization increasingly directed its funds to education and advocacy, along with research funding. This included lobbying insurance companies to pay for CGM devices, educating patients on how to advocate for themselves, and lobbying Congress for more NIH funding.
The Russian Empire organized its Cossacks into several voiskos (hosts), which lived along the Russian border and internal borders between Russian and non-Russian peoples. Each host originally had its own leadership, ranks, regalia, and uniforms. By the late 19th century, ranks were standardized following the example of the Imperial Russian Army. The ranks and insignia were kept after the 1988 law allowing the hosts to reform, and the 2005 law legally recognizing the hosts as a combat service. They are given below as per all military tickets that are standard for the Russian Army.
In 2026 Song and colleagues described Eoceras shaanxiense, a siphuncle-bearing cephalopod, based on fossils from the Early Cambrian Shuijingtuo Formation of China, making it the earliest known definitive cephalopod at the time of its discovery. Early cephalopods were likely predators near the top of the food chain. After the late Cambrian extinction led to the disappearance of many radiodonts, predatory niches became available for other animals. During the Ordovician period, the primitive cephalopods underwent pulses of diversification to become diverse and dominant in the Paleozoic and Mesozoic seas. In the Early Palaeozoic, their range was far more restricted; they were mainly confined to sublittoral regions of shallow shelves of the low latitudes, and usually occurred in association with thrombolites. A more pelagic habit was gradually adopted as the Ordovician progressed. Deep-water cephalopods, whilst rare, have been found in the Lower Ordovician – but only in high-latitude waters. The mid-Ordovician saw the first cephalopods with septa strong enough to cope with the pressures associated with deeper water, and could inhabit depths greater than 100–200 m. The direction of shell coiling would prove to be crucial to the future success of the lineages; endogastric coiling would only permit large size to be attained with a straight shell, whereas exogastric coiling – initially rather rare – permitted the spirals familiar from the fossil record to develop, with their corresponding large size and diversity.
Raw veneer has no backing on it and can be used with either side facing up. The two sides will appear different when a finish has been applied due to the cell structure of the wood. Paper backed veneer is as the name suggests, veneers that are backed with paper. The advantage to this is it is available in large sizes, or sheets, as smaller pieces are joined prior to adding the backing. This is helpful for users that do not wish to join smaller pieces of raw veneers together. This is also helpful when veneering curves and columns as the veneer is less likely to crack. Phenolic backed veneer is less common and is used for composite, or artificial wood veneers. Due to concern for the natural resource, this is becoming more popular. It too has the advantage of being available in sheets, and is also less likely to crack when being used on curves. Laid up veneer is raw veneer that has been joined to make larger pieces. The process is time-consuming and requires great care, but is not difficult and requires no expensive tools or machinery. Veneers can be ordered through some companies already laid up to any size, shape or design. Reconstituted veneer is made from fast-growing tropical species. Raw veneer is cut from a log, and dyed if necessary. Once dyed, the sheets are laminated together to form a block. The block is then sliced so that the edges of the laminated veneer become the “grain” of the reconstituted veneer. Wood on Wood Also called 2-ply is a decorative wood veneer face with a utility grade wood backer applied at an opposing direction to the face veneer.
Among marine animals, eels are resistant to sea snake venoms, which contain complex mixtures of neurotoxins, myotoxins, and nephrotoxins, varying according to species. Eels are especially resistant to the venom of sea snakes that specialise in feeding on them, implying coevolution; non-prey fishes have little resistance to sea snake venom. Clownfish always live among the tentacles of venomous sea anemones (an obligatory symbiosis for the fish), and are resistant to their venom. Only 10 known species of anemones are hosts to clownfish and only certain pairs of anemones and clownfish are compatible. All sea anemones produce venoms delivered through discharging nematocysts and mucous secretions. The toxins are composed of peptides and proteins. They are used to acquire prey and to deter predators by causing pain, loss of muscular coordination, and tissue damage. Clownfish have a protective mucus that acts as a chemical camouflage or macromolecular mimicry preventing "not self" recognition by the sea anemone and nematocyst discharge. Clownfish may acclimate their mucus to resemble that of a specific species of sea anemone.
Sources: en.wikipedia.org
== Function == This gene encodes a transmembrane transporter that likely plays a role in monocarboxylic acid transport. A mutation in this gene has been associated with juvenile cataracts with microcornea and renal glucosuria. [provided by RefSeq, Mar 2010].
Large sums from drug revenues were brought in from Miami and elsewhere to Panama for laundering, and Noriega received protection payments in these instances as well. American Steven Kalish also began a large scale business selling drugs, laundering money and selling hardware to the Panamanian military for considerable profits with Noriega's assistance. Dinges writes that at the time of the 1984 election, Kalish was preparing to ship a load of marijuana worth U.S. $1.4 million through Panama, for which Noriega had agreed to provide false Panamanian customs stamps; Noriega was to be paid $1 million for this exercise. Beginning in 1984, Noriega appeared to reduce the scale of his operations, and even ordered a raid against a cocaine factory in the interior of Panama, a raid which he then emphasized as evidence of his cooperation with the U.S. in their fight against drugs. He also ordered a crackdown on money laundering by Colombian cartel figures Jorge Ochoa and Gilberto Rodríguez Orejuela. Noriega's new image as an opponent of drug trafficking was symbolized by his being invited as a speaker in 1985 to Harvard University, for a conference on the role of the military in Central America's wars, a speech which received a lot of attention in Panama's pro-government press. In 1986, a convoluted operation involving the East German Stasi and the Danish ship Pia Vesta ultimately aimed to sell Soviet arms and military vehicles to South Africa's Armscor, with the Soviets using various intermediaries to distance themselves from the deal.
A farmer, George Smith, working under landlord the Duke of Gordon, was the first person in Scotland to take out a licence for a distillery under the new act, founding the Glenlivet Distillery in 1824, to make single malt Scotch. Some of the distilleries which started legal operations in the next few years included Bowmore, Strathisla, Balblair, and Glenmorangie; all remain in business today. Two events helped to increase whisky's popularity. The first was the introduction in 1831 of the column still. Aeneas Coffey patented a refined version of a design originally created by Robert Stein, based on early innovations by Anthony Perrier, for the new type of still which produced whisky much more efficiently than the traditional pot stills. The column still allowed for continuous distillation, without the need for cleaning after each batch was made. This process made manufacturing more affordable by performing the equivalent of multiple distillation steps. The new still dramatically increased production and the resultant whisky was less intense and smoother, making it more popular. Secondly, there was a shortage of wine and brandy in France, significant by 1880, due to phylloxera, a parasitic insect, destroying many vineyards, which led to a surge in demand for whisky. By the 1890s, almost forty new distilleries had opened in Scotland. In a speculative boom, the Edinburgh blenders Pattisons Ltd. came to prominence before spectacularly failing. In the downturn, The Distillers Company were able to buy up other firms' assets.
Research and Development, a "non-combative" modification that has been likened to Portal, in which the player uses the gravity gun and other aspects of the Source engine physics to solve puzzles and progress forward. Rexaura, a Portal modification developed by Ben "Mevious" Bryant featuring 20 (from 00 to 19) puzzles designed around manipulating and ricocheting energy pellets. Riot Act - A mod set in the Half-Life 2 universe, following a member of the civilian resistance on their escape from the Combine prison at Nova Prospekt.
==== Metabolism and elimination ==== When taken orally, about 95% of a dose of estradiol is metabolized in the intestines and liver into estrone and estrogen conjugates such as estrone sulfate, estrone glucuronide, and estradiol sulfate, among others, prior to entering the circulation. As a result, circulating estrone and estrogen conjugate levels are markedly elevated, in a highly unphysiological manner, with oral estradiol. Whereas the ratio of circulating estradiol to estrone is about 1:1 in premenopausal women and with transdermal estradiol, oral estradiol produces a ratio of about 1:5 on average and as high as 1:20 in some women. In addition, whereas levels of estradiol with menopausal replacement dosages of oral estradiol are in the range of the follicular phase of the normal menstrual cycle, levels of estrone resemble those during the first trimester of pregnancy. Moreover, whereas normal physiological estrone sulfate levels are 10 to 25 times higher than those of estradiol and estrone in premenopausal women, levels of estrone sulfate with oral estradiol are an additional 8 to 20 times higher than normal premenopausal or postmenopausal estrone sulfate levels. One study found that estrone sulfate levels were 200-fold higher than estradiol levels with 2 mg/day oral micronized estradiol or oral estradiol valerate, and estrone sulfate levels can reach up to nearly 1,000-fold higher concentrations than estradiol in some cases.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。